Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies

doi:10.3389/fphar.2022.1012552

HFCAS OpenIR

	Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies
	Wu, Xiaofan; Yang, Hongjian; Yu, Xingfei; Qin, Jiang-Jiang
	2022-09-23
发表期刊	FRONTIERS IN PHARMACOLOGY
通讯作者	Yu, Xingfei(yuxf1177@zjcc.org.cn) ; Qin, Jiang-Jiang(jqin@ucas.ac.cn)
摘要	Breast cancer is one of the most common malignancies and the leading cause of cancer-related death in women. HER2 overexpression is a factor for poor prognosis in breast cancer, and anti-HER2 therapy improves survival in these patients. A dual-targeted combination of pertuzumab and trastuzumab, alongside cytotoxic chemotherapy, constitutes the primary treatment option for individuals with early-stage, HER2-positive breast cancer. Antibody-drug conjugate (ADC) and tyrosine kinase inhibitors (TKI) also increase the prognosis for patients with metastatic breast cancer. However, resistance to targeted therapy eventually occurs. Therefore, it is critical to investigate how HER2-positive breast cancer is resistant to targeted therapy and to develop novel drugs or strategies to overcome the resistance simultaneously. This review aims to provide a comprehensive discussion of the HER2-targeted agents currently in clinical practice, the molecular mechanisms of resistance to these drugs, and the potential strategies for overcoming resistance.
关键词	HER2 breast cancer targeted therapy drug resistance overcoming strategies
DOI	10.3389/fphar.2022.1012552
关键词[WOS]	EPIDERMAL-GROWTH-FACTOR ; FACTOR RECEPTOR ; DOUBLE-BLIND ; TRASTUZUMAB RESISTANCE ; PI3K PATHWAY ; ANTIBODY ; HER2 ; PLACEBO ; GENE ; PERTUZUMAB
收录类别	SCI
语种	英语
资助项目	Qiantang Cross Fundation ; Wu Jieping Medical Foundation[320.6750.2021-10-30] ; Project of Zhejiang Medical and Health Science and Technology Program[2020KY491]
项目资助者	Qiantang Cross Fundation ; Wu Jieping Medical Foundation ; Project of Zhejiang Medical and Health Science and Technology Program
WOS研究方向	Pharmacology & Pharmacy
WOS类目	Pharmacology & Pharmacy
WOS记录号	WOS:000869974800001
出版者	FRONTIERS MEDIA SA
引用统计	被引频次：27[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/129479
专题	中国科学院合肥物质科学研究院
通讯作者	Yu, Xingfei; Qin, Jiang-Jiang
作者单位	Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC, Chinese Acad Sci,Canc Hosp, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Wu, Xiaofan,Yang, Hongjian,Yu, Xingfei,et al. Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies[J]. FRONTIERS IN PHARMACOLOGY,2022,13.
APA	Wu, Xiaofan,Yang, Hongjian,Yu, Xingfei,&Qin, Jiang-Jiang.(2022).Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies.FRONTIERS IN PHARMACOLOGY,13.
MLA	Wu, Xiaofan,et al."Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies".FRONTIERS IN PHARMACOLOGY 13(2022).